On August 29, 2023, Sinovac Holdings Biotechnology Co., Ltd. (hereinafter referred to as 'Sinovac Holdings') announced that its subsidiary Beijing Sinovac Biological Products Co., Ltd. (hereinafter referred to as 'Beijing Sinovac') has completed the change of business license.
The legal representative of Beijing Kexing is Mr. Yin Weidong.
Beijing Haidian District Market Supervision and Administration Bureau conducted an investigation on the industrial and commercial registration information of shareholders and legal representatives of Beijing Kexing in accordance with the 'Notice of Assistance in Enforcement', 'Enforcement Ruling' and 'Civil Mediation Letter' of the People's Court of Zhangdian District, Zibo City, Shandong Province. changed. Sinovac Holdings' wholly-owned subsidiaries Sinovac Holdings (Hong Kong) Co., Ltd. and Shandong Weiming Biomedical Co., Ltd. hold 73.09% and 26.91% of Beijing Sinovac's equity, respectively. Mr. Yin Weidong is the legal representative and chairman of Beijing Kexing. The Market Supervision Bureau of Haidian District, Beijing issued an updated business license dated August 25, 2023 to Beijing Kexing.
In the future, Sinovac will continue to adhere to the mission of 'providing vaccines for the elimination of human diseases' and provide high-quality vaccine products for the prevention and control of global infectious diseases.
About SINOVAC
Sinovac Biotech Ltd. (Sinovac Biotech Ltd., SINOVAC Kexing) is a leading biological high-tech enterprise in China. With the mission of 'providing vaccines for the elimination of human diseases', it is committed to the research of human vaccines and related products, Development, production and sales, providing services for global disease prevention and control.
The vaccines developed by SINOVAC mainly include vaccines against common infectious diseases such as viral hepatitis, influenza, pneumonia, polio, chicken pox, and mumps, as well as against SARS, H5N1 avian influenza, H1N1 influenza, EV71 hand, foot and mouth disease, new Vaccines for new and sudden infectious diseases such as coronavirus infection.
The company's existing 4 vaccines have passed the pre-certification of the World Health Organization (inactivated hepatitis A vaccine, inactivated polio vaccine of Sabin strain, live attenuated varicella vaccine) or included in the emergency use list (inactivated vaccine of new coronavirus), the quality of the vaccine The management system has been recognized by international organizations and multinational drug regulatory authorities.
SINOVAC is constantly exploring opportunities in the international market, and has exported vaccines to dozens of countries and international organizations.
Contact:
Tel: +86-10-8279 9720
Email: ir@sinovac.com
Web: www.sinovac.com
SINOVAC BIOTECH LTD. 